2023 GREAT PLACE TO WORK SURVEY DEFINES KARMA GLOBAL AS A GREAT PLACE TO WORK DUE TO A WIDE VARIETY OF CRITERIA LIKE QUALITY OF LEADERSHIP, CULTURE, DEVELOPMENT OPPORTUNITIES, DIVERSITY, EQUALITY AND INCLUSION!
Karma Global is a tech-enabled consulting organization made up of industry specialists who provide professional advice, direction, and practical solutions to organizations with problems they can’t solve on their own. From its vast experience of 2 decades, it has witnessed that every organization somehow gets confronted with problems and issues which can be efficiently resolved with the help of Organizations like Karma Global who have experts on their panel to quickly address and leave the web of complexities behind.
Karma Global is an HR & Compliance dominated Consulting firm having its headquarters in Mumbai India and foreign offices in Canada, the US, the UK, UAE and South East India. It offers solutions with AI tech products which have every required feature and module built into the various offerings.
Self-regulation in the MSME pharma sector is the need of the hour says Union Minister of Chemicals & Fertilizers Dr. Mansukh Mandaviya
Schedule M to be soon made compulsory for MSME Pharma Cos:
Union Minister of Chemicals & Fertilizers Dr. Mansukh Mandaviya meets representatives from MSME Pharma Companies, stresses on need for self-regulation in MSME pharma sector
“It is important for MSME Pharma Cos. to be alert to the quality of drugs and expeditiously move towards Good Manufacturing Processes through self-regulation”
Schedule M is to be soon made compulsory for MSME Pharma Cos
“There shall be no compromise with the quality of drugs manufactured in India”
Stringent action to be taken against companies that make spurious drugs- Dr. Mansukh Mandaviya
Aimed at ensuring the robust quality of pharma products, the Union Minister of Chemicals and Fertilizers Mansukh Mandaviya has directed regulatory authorities to conduct risk-based inspections and audits of manufacturing plants. He also added that Schedule M shall be made compulsory for the MSME pharma sector in a phased manner.
“This will help in quality assurance and also reduce compliance burden,’’ he said.
What is schedule M
Schedule M part of Drugs and Cosmetics Act 1940 deals with ‘Good Manufacturing Practices’ for pharmaceuticals that should be followed by pharmaceutical manufacturing units in India. The Union government on Tuesday said that it would make rules for good manufacturing practices compulsory for pharmaceutical companies belonging to the MSME sector in a phased manner even though compliance to such practices were made mandatory by law more than two decades ago.
Union Health and Pharmaceutical Minister Mansukh Mandaviya met the representatives of the medium and small scale industries and told them that GMP practices shall be made compulsory for them in a phased manner, causing confusion among the stakeholders.
While some of the companies said they didn’t understand what the government intended to do since compliance of Schedule M – the section in the Drugs and Cosmetics Act that deals with GMP norms – was a must to obtain manufacturing licenses.
The MSME sector, on the other hand, argued that strict implementation of Schedule-M would involve a lot of investment – probably in the range of Rs 8-10 crore – and they simply could not afford it. It will make more economic sense for them to wind up their operations rather than spending such an amount on GMP norms.
“Schedule M is the soul of quality. Yet for politico-economic compulsions and financial implications for the industry both the regulators and the regulated have been dragging their feet,” C M Gulhati, an industry veteran and editor of Monthly Index of Medical Specialities said. “The implementation has both ‘software’ and ‘hardware’ implications.”
While software includes employment of qualified quality staff, purchase of machinery and strict implementation of standard operating procedures, for most small and medium industries the problem lies in hardware because it involves new locations, environment and above all separate buildings for formulation units.
Some of the stipulations mean that industrial units are to be relocated while in other cases, old buildings are needed to be demolished and new constructions will be required to meet Schedule M conditions. “This is easier said than done,” Gulhati said.
With the quality of Indian medicines under scanner after multiple made-in-India cough-syrup triggered adverse health incidents in foreign countries, Mandaviya said Schedule M would be made compulsory for the MSME pharma sector in a phased manner.
“This will help in quality assurance and also reduce compliance burden he said, noting that the government had zero tolerance towards manufacturers not adhering to quality compliance and making spurious medicines.
What the experts have to say ………!
Experts, outside the government, hold a different view. “The government had given substantial concessions to MSMEs existing in 2001 from compliance with Schedule M. I have no confidence that this recent directive will be implemented properly,” commented Dinesh Thakur, the whistle-blower against Ranbaxy Pharmaceuticals.
“How exactly are they going to monitor compliance? The State Drug Regulators, who are tasked with inspections and ensuring compliance have no incentive to enforce such a directive,” said Thakur, the co-author of a book titled Truth Pill on Indian pharmaceutical industry.
Proprietary blog of Karma Global
This blog has been collated and compiled by the internal staff of Karma Global with the knowledge and expertise that they possess, besides adaptation, illustration, derivation, transformation, collection from various sources, for its monthly newsletter Issue 14 of August 2023 and in case of specific or general information or compliance updates for that matter, kindly reach out to the Marketing Team – Kush@karmamgmt.com / yashika@karmamgmt.com